Rare disease focus Target opportunities in rare disease therapies leveraging Mereo BioPharma’s portfolio including Osteogenesis Imperfecta and Alpha-1 Antitrypsin Deficiency-associated Lung Disease to align with specialized payers, patient access programs, and specialty distributors.

In-licensing to Phase 3 Capitalize on Mereo’s track record of advancing in-licensed assets to Phase 3 quickly; propose partnerships or co-development options to accelerate late-stage candidates and share development and commercialization risks.

Strategic collaborations Engage Sentynl Therapeutics and potential regional partners for co-promotion or licensing of alvelestat and other candidates; explore non-dilutive funding, milestone-based deals, or strategic collaborations to expand geographic reach.

Regulatory and reimbursement readiness Position services around navigating complex reimbursement and market access for rare diseases, offering advisory, payer engagement, and health economics outcomes research to accelerate market entry and sustainable pricing.

Financial and litigation risk awareness Acknowledge ongoing investor-related litigation activity; tailor sales and BD outreach with clear timelines and transparent governance discussions, offering robust diligence support and risk mitigation narratives to potential partners.